Home > Boards > US Listed > Medical - Drugs >

ZymoGenetics (ZGEN)

ZGEN RSS Feed
Add ZGEN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/11/2010 2:10:12 AM - Followers: 9 - Board type: Free - Posts Today: 0

http://www.zymogenetics.com/

http://finance.yahoo.com/q/ks?s=ZGEN

http://finance.google.com/finance?client=ob&q=ZGEN

http://www.form4oracle.com/company?cik=0001129425&ticker=ZGEN

ZymoGenetics, Inc. engages in the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases in the areas of hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its preclinical stage internal products include IL-31, for the treatment of atopic dermatitis and inflammatory diseases. The company's phase II internal candidates comprise atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and IL-21 for the treatment of metastatic melanoma/metastatic renal cell carcinoma. Its phase I out-licensed candidates consist of rFactor XIII for congenital factor XIII deficiency and cardiac surgery. ZymoGenetics also develops rhThrombin, a phase III product, for the treatment of general surgical hemostat and line extensions; and PEG-Interferon lambda, which is in phase I clinical trial for the treatment of hepatitis C virus infection. In addition, it provides six out-licensed products, which include Novolin and NovoRapid, which are used in the treatment of diabetes; NovoSeven for use in the treatment of hemophilia; Regranex for wound healing; GEM 21S for the treatment of periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor, which is used for the treatment of myocardial infarction. ZymoGenetics has a strategic alliance with Merck Serono S.A for the research, development, and commercialization of novel protein and antibody therapeutics derived from the company's proprietary portfolio of genes and proteins; and a collaboration with Bayer HealthCare for the development and commercialization of recombinant human thrombin. The company was founded in 1981 and is headquartered in Seattle, Washington.

ZGEN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#125   I think it’s presumptuous of you to assume iwfal 09/11/10 02:10:10 AM
#124   How much market share do generics normally capture…? DewDiligence 09/10/10 04:11:35 AM
#122   All-oral regimens will likely take the bulk of iwfal 09/08/10 03:08:48 PM
#121   A few reasons: DewDiligence 09/08/10 12:29:17 PM
#120   wow missed this one! Nice!! Tina 09/08/10 12:21:42 PM
#119   Even if interferons stay around in HCV therapy iwfal 09/08/10 12:17:36 PM
#117   …I substantially disagree - but it isn't worth DewDiligence 09/08/10 12:09:03 PM
#116   You still have 136 other boards to worry DewDiligence 09/08/10 12:03:21 PM
#115   Another biotech buyout & time to drop the surf1944 09/08/10 09:33:43 AM
#114   Dew assumes a fairly high degree of probability iwfal 09/08/10 08:25:20 AM
#113   Assuming you are right about the first, Hep brooklyn137 09/08/10 07:58:27 AM
#112   They announced that they were starting a hep DewDiligence 09/08/10 02:16:52 AM
#111   They announced that they were starting a hep brooklyn137 09/08/10 01:45:34 AM
#110   oh..i didnt know that..i jsut saw that shareholder newbie65 09/08/10 12:49:23 AM
#109   Your milestone figure includes $287M of clinical/regulatory milestones DewDiligence 09/07/10 10:25:58 PM
#108   Correction, the milestones are not yet due, but brooklyn137 09/07/10 09:49:48 PM
#107   This is a horrible thing. If you brooklyn137 09/07/10 09:48:41 PM
#106   isnt this a good thing? why are they newbie65 09/07/10 08:04:31 PM
#105   Bristol-Myers agrees to buy ZymoGenetics for $885M surf1944 09/07/10 07:49:27 PM
#104   ZGEN SHORT INTEREST fourkids_9pets 09/07/10 06:49:34 PM
#103   ZymoGenetics Sold to Bristol-Myers Squibb for $9.75 a fourkids_9pets 09/07/10 05:34:22 PM
#102   It's odd that the PR does not say DewDiligence 08/25/10 09:26:32 AM
#101   12 weeks will be up on November 17. brooklyn137 08/25/10 09:13:11 AM
#100   ZymoGenetics Announces Completion of Enrollment in Phase 2b surf1944 08/25/10 08:32:24 AM
#99   UPDATE 1-Zymogenetics posts narrower Q2 loss, shares rise surf1944 08/04/10 08:38:59 AM
#98   ZGEN: $4.50 mlkrborn 06/25/10 02:00:55 PM
#97   Zymogenetics ZGEN UBS Neutral » Buy $6.50 surf1944 06/23/10 01:59:34 PM
#96   ZymoGenetics rises on analyst 'Outperform' rating surf1944 06/10/10 04:16:28 PM
#95   ZymoGenetics skin cancer drug meets study goal surf1944 06/07/10 07:31:41 AM
#94   ZymoGenetics Initiates PEG-Interferon lambda Phase 2b Clinical Trial surf1944 06/02/10 08:58:23 AM
#93   ZymoGenetics Announces Upcoming Presentation of Positive IL-21 Phase surf1944 05/20/10 06:44:28 PM
#92   ZymoGenetics Reports First Quarter 2010 Financial Results surf1944 05/04/10 04:10:43 PM
#91   Amino acid substitution in HCV core region and iwfal 04/16/10 02:28:17 PM
#90   ZymoGenetics to Host Conference Call and Webcast on surf1944 04/16/10 12:16:51 PM
#89   Pointer to PROVE3 Thread on another board: iwfal 03/04/10 06:59:06 AM
#88   Data on Flurizan failed AD trial from Murko iwfal 02/10/10 11:13:26 PM
#87   6:10AM Zymogenetics announces new publication supports safety profile surf1944 02/02/10 08:57:29 AM
#86   ZymoGenetics Inc. said it has begun a public surf1944 01/07/10 08:02:43 AM
#84   4:32PM Zymogenetics and Bayer restructure RECOTHROM agreements (ZGEN) surf1944 12/21/09 11:54:13 PM
#83   Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b surf1944 11/01/09 10:31:30 AM
#82   ZymoGenetics shares fall on Oppenheimer downgrade GuruTrader 10/26/09 11:33:36 AM
#81   UPDATE 1-Zymogenetics says Merck Serono discontinues MS trials surf1944 09/28/09 08:58:56 AM
#80   has news Stock 01/12/09 07:11:23 PM
#79   Oversold with an Improving RSI (ZGEN) from stockcharts.com surf1944 09/18/08 08:16:32 PM
#78   UBS reiterates "BUY" and reduced 12-month price target CHM_760 09/04/08 11:42:41 AM
#77   ZymoGenetics and Merck Serono Restructure Partnership surf1944 09/03/08 08:17:54 AM
#76   ZymoGenetics Earns Milestone Payment for RECOTHROM(R) European Filing surf1944 09/02/08 09:20:39 AM
#75   ZymoGenetics Reports Second Quarter 2008 Financial Results surf1944 08/06/08 09:47:58 AM
#74   The funds seem to still be in ZGEN surf1944 07/20/08 11:58:11 AM
#73   Surf thanks for keeping the board active. It biomund 06/30/08 09:27:32 PM
PostSubject